Results 161 to 170 of about 4,340 (195)

Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability

Pharmaceuticals, 2019
ZL277 is a prodrug of belinostat with enhanced bioavailability and efficacy as a pan histone deacetylase (HDAC) inhibitor. In this study, we investigated the metabolism and pharmacokinetics of ZL277 in liver S9 fractions, liver microsomes, liver cytosol,
Changde Zhang, Shanchun Guo, Qiu Zhong   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Belinostat: clinical applications in solid tumors and lymphoma

Expert Opinion on Investigational Drugs, 2011
Histone deacetylase (HDAC) inhibitors have recently emerged as a novel and active class of anticancer agents. Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma.A literature search of pre-clinical and clinical ...
L Rhoda Molife, Johann S de Bono
exaly   +3 more sources

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

Cancer, 2015
BACKGROUND: The objective of this study was to evaluate the efficacy of belinostat, a histone deacetylase inhibitor, when added to paclitaxel/carboplatin in the empiric first-line treatment of patients with carcinoma of unknown primary site (CUP).METHODS:
Gedske Daugaard, Gerdt Hübner, F Anthony Greco   +2 more
exaly   +2 more sources

Belinostat for the treatment of peripheral T-cell lymphomas

Drugs of Today, 2014
Belinostat is a novel histone deacetylase (HDAC) inhibitor that is being developed in various solid tumors and hematologic malignancies. HDACs have been found to be important in the epigenetic regulation of cancer progression and inhibition of these molecules in preclinical studies induces cancer cell apoptosis and prevents tumor growth.
J, McDermott, A, Jimeno
openaire   +2 more sources

Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat

Lung Cancer, 2017
To investigate and elucidate the mechanism for the potentiation of cisplatin anticancer activity by belinostat in platinum (Pt)-resistant lung cancer cells.Combination of cisplatin and belinostat was investigated in two pairs of parental and cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines.
Kenneth K W To, Liwu Fu
exaly   +3 more sources

Belinostat for the treatment of T-cell lymphoma

Expert Opinion on Orphan Drugs, 2014
Introduction: T-cell lymphomas are a rare and heterogeneous group of malignant diseases that, for the most part, are associated with a very poor prognosis. Advances in understanding lymphoma biology and molecular pathogenesis coupled with interesting empiric observations have yielded many promising new therapeutic targets.
Ahmed Sawas, Owen A O’Connor
openaire   +1 more source

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

Expert Opinion on Investigational Drugs, 2009
Belinostat is a potent hydroxamate-type histone deacetylase inhibitor with a broad antineoplastic activity in a spectrum of preclinical tumor models and with demonstrated clinical efficacy in the still very early clinical trial program. Belinostat has been relatively well tolerated following both i.v.
Peter Gimsing
exaly   +3 more sources

Belinostat: First Global Approval

Drugs, 2014
Belinostat [Beleodaq(®) (US)], a small-molecule hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
openaire   +2 more sources

A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity

Journal of Inorganic Biochemistry, 2013
The successful design and synthesis of a novel Pt complex of the histone deacteylase inhibitor belinostat are reported. Molecular modelling assisted in the identification of a suitable malonate derivative of belinostat (mal-p-Bel) for complexation to ...
Darren M Griffith, Anthony J Chubb, Marian Brennan   +2 more
exaly   +1 more source

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Future Oncology, 2015
The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven effective for the treatment of relapsed/refractory PTCL.
Armin, Rashidi, Amanda F, Cashen
openaire   +2 more sources